Abstract
The vascular endothelial growth factor (VEGF)/VEGF receptor pathways are essential for the regulation of angiogenesis during embryonic development and tumor progression. VEGF receptor 1 (VEGFR-1) has been shown to promote tumor growth and metastasis through the regulation of multiple biological functions in cancer cells, vasculature, stroma and other tumor-associated cells. VEGFR-1 signaling is required for the survival of endothelial cells and macrophages and the mobilization of cancer cells, endothelial cells, myeloid progenitors, and monocyte/macrophages. VEGFR- 1 was reported to have a function in eliciting epithelial-to-mesenchymal transition in cancer cells toward invasive and metastatic phenotype. Furthermore, VEGFR-1 was found to promote metastasis through initiating pre-metastatic niche by VEGFR-1 positive bone marrow progenitors. It was reported that VEGFR-1 had an active role in promoting inflammation through modulating immune cells and mediating immunosuppression by VEGFR-1 positive myeloid cells. Given that VEGFR-1 has a multi-functional role in promoting angiogenesis, inflammation, tumor growth and metastasis, VEGFR-1 has emerged as a promising therapeutic target for treatment of cancer as well as angiogenesis and inflammation associated disorders.
Current Medicinal Chemistry
Title: Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Volume: 16 Issue: 22
Author(s): Yan Wu and Zhenping Zhu
Affiliation:
Abstract: The vascular endothelial growth factor (VEGF)/VEGF receptor pathways are essential for the regulation of angiogenesis during embryonic development and tumor progression. VEGF receptor 1 (VEGFR-1) has been shown to promote tumor growth and metastasis through the regulation of multiple biological functions in cancer cells, vasculature, stroma and other tumor-associated cells. VEGFR-1 signaling is required for the survival of endothelial cells and macrophages and the mobilization of cancer cells, endothelial cells, myeloid progenitors, and monocyte/macrophages. VEGFR- 1 was reported to have a function in eliciting epithelial-to-mesenchymal transition in cancer cells toward invasive and metastatic phenotype. Furthermore, VEGFR-1 was found to promote metastasis through initiating pre-metastatic niche by VEGFR-1 positive bone marrow progenitors. It was reported that VEGFR-1 had an active role in promoting inflammation through modulating immune cells and mediating immunosuppression by VEGFR-1 positive myeloid cells. Given that VEGFR-1 has a multi-functional role in promoting angiogenesis, inflammation, tumor growth and metastasis, VEGFR-1 has emerged as a promising therapeutic target for treatment of cancer as well as angiogenesis and inflammation associated disorders.
Export Options
About this article
Cite this article as:
Wu Yan and Zhu Zhenping, Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders, Current Medicinal Chemistry 2009; 16 (22) . https://dx.doi.org/10.2174/092986709788803169
DOI https://dx.doi.org/10.2174/092986709788803169 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Interleukin-2 Immunotherapy and AIDS-Related Cytomegalovirus Retinitis
Current HIV Research Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem
Current Pharmaceutical Design Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines
Letters in Drug Design & Discovery Current Status of Delivery Systems to Improve Target Efficacy of Oligonu-cleotides
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities
Current Medicinal Chemistry TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics